checkAd

Angle PLC Announces Issue of Equity

Exercise of Options and Total Voting RightsGUILDFORD, SURREY / ACCESSWIRE / December 2, 2022 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that following the exercise of employee options, it has issued and …

Exercise of Options and Total Voting Rights

GUILDFORD, SURREY / ACCESSWIRE / December 2, 2022 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that following the exercise of employee options, it has issued and allotted 56,666 new ordinary shares of £0.10 each ("New Ordinary Shares") in the Company. The New Ordinary Shares will rank pari passu with the existing Ordinary Shares in the Company.

An application has been made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective, and trading will commence at 8.00 a.m. on 7 December 2022. Following Admission, the total number of Ordinary Shares in issue, and therefore the total number of voting rights, will be 260,580,547.

For further information:

ANGLE plc

+44 (0) 1483 343434

Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Andrew Holder, Head of Investor Relations


Berenberg (NOMAD and Joint Broker)
Toby Flaux, Ciaran Walsh, Milo Bonser

+44 (0) 20 3207 7800

Jefferies (Joint Broker)
Max Jones, Thomas Bective

+44 (0) 20 7029 8000

FTI Consulting
Simon Conway, Ciara Martin
Matthew Ventimiglia (US)


+44 (0) 203 727 1000
+1 (212) 850 5624

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the EU Market Abuse Regulation (596/2014). Upon the publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/

Notes for editors

About ANGLE plc www.angleplc.com

ANGLE is a world leading liquid biopsy company with sample-to-answer solutions. ANGLE's proven patent protected circulating tumor cell (CTC) harvesting technology is known as the Parsortix® system.

Seite 1 von 3


Wertpapier



0 Kommentare
Nachrichtenquelle: Accesswire
 |  107   |   |   

Schreibe Deinen Kommentar

Disclaimer

Angle PLC Announces Issue of Equity Exercise of Options and Total Voting RightsGUILDFORD, SURREY / ACCESSWIRE / December 2, 2022 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that following the exercise of employee options, it has issued and …

Nachrichten des Autors

248 Leser
176 Leser
160 Leser
148 Leser
144 Leser
144 Leser
116 Leser
116 Leser
116 Leser
112 Leser
308 Leser
304 Leser
296 Leser
292 Leser
268 Leser
260 Leser
248 Leser
248 Leser
244 Leser
236 Leser
820 Leser
792 Leser
788 Leser
788 Leser
748 Leser
696 Leser
664 Leser
624 Leser
592 Leser
576 Leser
4532 Leser
2859 Leser
1735 Leser
1621 Leser
1284 Leser
1255 Leser
1244 Leser
1125 Leser
1072 Leser
942 Leser